Recent Articles

• 
  Bio

  "Korean Bio Platforms Attract Global Pharma Interest"

  The domestic bio market is experiencing a revival. Recently, domestic bio companies have succeeded in exporting technology worth trillions of KRW, leading to a diversification of investment funds from semiconductor stocks to bio stocks. The driving force behind the 'second bio spring' following the

  2025.11.18
• 
  MedTech

  Korea University Medical Center Launches Particle Therapy Project

  Provided by Korea University Medical Center Korea University Medical Center announced on the 17th that it will officially commence the 'Particle Therapy Hub Establishment' project, which is expected to mark a new turning point in domestic cancer treatment.A representative from Korea University Medic

  2025.11.17
• 
  Tech / Robot / FDA

  EndoRobotics: Endoscopic Surgery Robot Gains FDA Approval

  "Endorobotics possesses world-class technology based on extensive research by medical professionals and robotics technology."In the early 19th century, doctors used candles and mirrors to look inside the human body. With the introduction of fiber optic technology in the 1950s, endoscopes finally bec

  2025.11.17
• 
  Bio / R&D

  Jefit Wins CES 2026 Innovation Award for Onco-FIT

  Photo courtesy of Zefit Zefit announced on the 17th that it received the Innovation Award in the 'Human Security' category at 'CES 2026', the world's largest IT and electronics exhibition. This award recognizes the innovation of Zefit's patient-customized zebrafish avatar-based anticancer drug sensi

  2025.11.17
• 
  Bio / R&D

  Alteogen Eyes KOSPI, Targets 60% Profit Margin

  Alteogen Headquarters and Research Institute Alteogen announced on the 14th through a disclosure that it achieved consolidated sales of KRW 49 billion and an operating profit of KRW 26.7 billion in the third quarter of this year. Compared to last year, sales grew by 900%, and operating profit turned

  2025.11.14
• 
  Global Expansion

  Daewoong Exports Diabetes Drug to 8 Latin Nations

  Daewoong Pharmaceutical Headquarters Daewoong Pharmaceutical announced on the 14th that it has signed an export contract for the diabetes treatment 'Enblo (ingredient name: Inavogliflozin)' with eight countries in Latin America. The contract is valued at approximately KRW 33.7 billion, and when comb

  2025.11.14
• 
  Celltrion

  Celltrion's Top 3 Drugs Lead Europe Prescriptions

  Celltrion's Third Plant Celltrion announced on the 13th that its three flagship autoimmune and oncology biologics have achieved the top prescription position in Europe, a key global market. According to pharmaceutical market research firm IQVIA, Celltrion's autoimmune disease treatment 'Remsima (act

  2025.11.13
• 
  Medical / Digital Healthcare

  "AI Quantifies Treatment: Alice Healthcare's VBC Solution"

  Alice Healthcare (CEO Kang Da-gyeom) announced on the 13th that it is actively introducing its VBC response solution in the United States, marking a significant step in its global market expansion. This introduction reflects the demand from the field to objectively prove treatment outcomes with data

  2025.11.13
• 
  Global Expansion

  ABL Bio Exports Technology to Eli Lilly for KRW 3.8 Trillion

  ABL Bio, a new drug development company, has successfully licensed its technology to global pharmaceutical company Eli Lilly in a deal worth up to KRW 3.8 trillion. This achievement comes seven months after a KRW 4 trillion technology export to GlaxoSmithKline (GSK) in April this year. ABL Bio annou

  2025.11.13
• 
  Global Expansion

  Korea United Pharm Discusses Exports with Malaysia Delegation

  Korea United Pharm Inc. announced on the 12th that it hosted a delegation from Malaysia's Ministry of Health, Ministry of Science, Technology and Innovation, National Pharmaceutical Regulatory Agency, and Malaysian Investment Development Authority to discuss research and production cooperation in th

  2025.11.12